The economic burden of non-influenza-related viral respiratory tract infection in the United States
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
Ultimately, though, the decision of when to receive a COVID vaccine is up to the individual and their personal care physician, department spokesperson Mark ONeill said in an email
Again, human time-course data is absent, so the following is informed inference from peptide pharmacology and animal work rather than measured human curves
Shop ALL premium quality Peptide Supplies here